Grandeur Peak Global Advisors LLC Sells 20,488 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Grandeur Peak Global Advisors LLC lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 40.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,055 shares of the medical research company's stock after selling 20,488 shares during the period. Grandeur Peak Global Advisors LLC owned approximately 0.06% of Charles River Laboratories International worth $5,548,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. EP Wealth Advisors LLC bought a new position in shares of Charles River Laboratories International in the third quarter worth approximately $273,000. National Bank of Canada FI grew its holdings in Charles River Laboratories International by 45.4% in the 3rd quarter. National Bank of Canada FI now owns 21,216 shares of the medical research company's stock worth $4,179,000 after acquiring an additional 6,627 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its position in shares of Charles River Laboratories International by 13.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company's stock valued at $3,071,000 after acquiring an additional 1,882 shares during the period. M&T Bank Corp raised its stake in shares of Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after acquiring an additional 66 shares during the last quarter. Finally, Toronto Dominion Bank boosted its holdings in shares of Charles River Laboratories International by 1.6% during the third quarter. Toronto Dominion Bank now owns 25,617 shares of the medical research company's stock worth $5,046,000 after purchasing an additional 397 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

CRL has been the subject of a number of recent analyst reports. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the company from $190.00 to $170.00 in a research report on Friday, March 21st. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Robert W. Baird cut their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $182.00.

Insider Activity

In other news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Birgit Girshick acquired 1,514 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Down 0.5 %

Charles River Laboratories International stock traded down $0.58 during mid-day trading on Tuesday, reaching $106.02. The stock had a trading volume of 2,845,054 shares, compared to its average volume of 880,553. The company has a market capitalization of $5.21 billion, a price-to-earnings ratio of 706.79, a PEG ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company has a 50-day moving average price of $154.31 and a two-hundred day moving average price of $175.73.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. During the same quarter in the prior year, the company posted $2.46 earnings per share. The business's revenue for the quarter was down 1.1% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).